` EMD (Emyria Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

EMD
vs
S
S&P/ASX 300

Over the past 12 months, EMD has significantly outperformed S&P/ASX 300, delivering a return of +49% compared to the S&P/ASX 300's +6% growth.

Stocks Performance
EMD vs S&P/ASX 300

Loading
EMD
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
EMD vs S&P/ASX 300

Loading
EMD
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
EMD vs S&P/ASX 300

Loading
EMD
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Emyria Ltd vs Peers

S&P/ASX 300
EMD
LLY
JNJ
ROG
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Emyria Ltd
Glance View

Market Cap
41.8m AUD
Industry
Pharmaceuticals

Emyria Ltd. is a healthcare technology and services company. The firm provides care for its patients through its clinics gathering real-world-evidence (RWE) insights in relation to therapies, such as cannabinoid-based medicines and drug development. Its evidence-based drug development program (EMD-003) is focused on mental health and EMD-004 is focused on irritable bowel syndrome (IBS). The Company’s subsidiaries include Emyria Clinical Network Pty Ltd and Openly Care Inc.

EMD Intrinsic Value
0.013 AUD
Overvaluation 76%
Intrinsic Value
Price
Back to Top